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PURPOSE: The purpose of this study was to investigate the significance of fascin expression in colorectal carcinoma. 
METHODS: This is a retrospective study of 167 consecutive, well-documented cases of primary colorectal adenocarcinoma for 
which archival material of surgical specimens from primary tumor resections were available. We chose a representative tissue 
sample block and examined fascin expression by immunohistochemistry using a primary antibody against “fascin”. We calculated 
the “immunohistochemical score (IHS)” of fascin for each case, which was calculated from the multiplication of scores for the 
percentage of stained cells and the staining intensity.
RESULTS: Fascin immunoreactivity was observed in 59 (35.3%) of all cases with strong reactivity in 24 (14.4%), moderate reac-
tivity in 25 (14.9%) and weak reactivity in 10 (6.0%) cases. Strong/moderate immunoreactivities were mostly observed in invasive 
fronts of the tumors or in both invasive and other areas. Fascin immunoreactivity scores were significantly higher in tumors with 
lymph node metastasis (p:0.002) and advanced stage presentation (p:0.007). There was no relation between fascin expression and 
age, gender, depth of invasion, distant metastasis or histological grade (p>0.05). There was a higher and statistically significant 
correlation between fascin immunoreactivity in the invasive borders of tumors and lymph node metastasis (r:0.747, p:0.005). In 
stage III/IV tumors, two-year survival was 92.2% in tumors without fascin immunoreactivity, and only 60.0% in tumors with a 
fascin IHS>10 (p:0.003). 
CONCLUSION: These findings suggest that fascin is heterogeneously expressed in approximately one third of colorectal carci-
nomas with a significant association with lymph node metastasis, tumor stage and location. Moreover, these results indicate that 
fascin may have a role in the lymph node metastasis of colorectal carcinomas. 
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INTRODUCTION
Gaining motility and migratory capacity are important 
steps in the neoplastic transformation of a cell, enabling 
invasion and the metastatic potential of a tumor. 
Malignant cells have the ability to migrate, which requires 
rearrangements of the actin cytoskeleton facilitated by actin 
binding proteins. Fascin is a 55 kDa actin-binding globular 
protein that is responsible for aggregating F-actin into well-
organized parallel bundles.1 Fascin binds beta-catenin, a 
molecule that is not only involved with cell-cell adhesion, 
but is also a component of the Wnt signaling pathway.2 The 
Wnt signaling pathway describes a complex network of 
proteins that are best known for their roles in embryogenesis 
and cancer. Moreover, this pathway is thought to play a key 
role in the occurrence of cancer stem cells. One regulator 
of the Wnt signaling pathway is sFRP1 (Secreted Frizzled 
Protein), which has the ability to bind Wnt proteins. When 
Wnt binds to sFRP, it cannot activate the Wnt signaling 
pathway. Beachy et al. found that sFRP expression is lost in 
colorectal and breast cancer.3 Fascin is expressed in normal 
mesenchymal, endothelial, dendritic and neuronal cells, but 
not in normal epithelia.4 Normal simple columnar epithelia 
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of the biliary duct, colon, ovary, pancreas and stomach are 
all negative for fascin.5 The expression of fascin in epithelial 
neoplasia has recently been described, with the finding that 
fascin expression is often up-regulated in several types of 
human neoplasms such as ovarian,6 breast,7 pancreatic,8 
lung,9 skin,10 brain,11 stomach12 and esophageal tumors.13 
In a cell culture model developed to examine the effect of 
fascin expression on the adhesive interactions, invasiveness 
and differentiation of colonic epithelial cells, Jawhari et 
al. reported marked effects on the organization of the actin 
cytoskeleton, cell-surface protrusions and focal adhesions in 
the absence of alterations in the protein levels of the major 
components of these structures. These effects correlate with 
alterations in cell movements on a two-dimensional matrix 
and an increased invasiveness in a three-dimensional matrix. 
The cells also showed increased proliferation and a decreased 
capacity for normal glandular differentiation in collagen 
gels.1 The forced expression of fascin in colorectal cancer 
cells increased their migration and invasion in cell culture and 
caused cell dissemination and metastasis in vivo. In contrast, 
the suppression of fascin expression by small interfering RNA 
reduced cell invasion. Although the expression of fascin in 
primary tumors correlated with the presence of metastases, 
fascin was not expressed in metastases themselves.14 
Few clinicopathologic studies have been conducted on 
fascin expression in colorectal carcinomas,15-17 and some 
were performed on tissue microarrays.15,17 In one study of 
syndecan-1 immunoreactivity in colon adenocarcinomas, 
loss of syndecan-1 expression was correlated with strong 
fascin staining in the stroma.18 In a study on fascin 
transcription, fascin up-regulation appeared to have multiple 
effects, with CREB and AhR playing roles in those effects.19 
Recently, it was demonstrated that Rac regulates the 
interaction of fascin with protein kinase C in cell migration 
in colon cancer cell lines.20 The aim of this study was to 
evaluate the immunohistochemical expression of fascin in 
conventional tissue sections of colorectal carcinomas and 
to analyze the relationship between fascin expression and 
clinicopathological features, TNM stage and patient survival. 
MATERIALS AND METHODS
Patients
This was a retrospective study of 167 consecutive, well-
documented cases of primary colorectal adenocarcinoma 
for which archival material of surgical specimens from 
primary tumor resections were available in the Department of 
Pathology of Gulhane Military Medical Academy. The patient 
sample consisted of 106 men and 61 women with a median 
age of 64 years (range 21–88 years). None of the patients had 
received chemotherapy or radiation before surgery. All cases 
were reviewed for differentiation according to the World 
Health Organization classification of colonic carcinomas. 
There were 6 (3.6%) grade 1, 131 (78.4%) grade 2 and 19 
(11.4%) grade 3 carcinomas. Ten cases (6%) were mucinous 
carcinomas and one (0.6%) was a signet ring cell carcinoma. 
According to the TNM system of colorectal cancer staging, 
tumors were classified as stage I (n =14), stage II [n =74, 21 
stage IIA (T3N0M0) and 53 stage IIB (T4N0M0) cases], stage 
III [n =50, 3 stage IIIA (T1-T2N1M0), 27 stage IIIB (T3-
T4N1M0) and 20 stage IIIC (anyTN2M0) cases] and stage IV 
(n =29, any T, any N M1 cases). The mean follow-up period 
for 151 patients was 28.29 months (range 1–67 months). The 
remaining 16 patients were lost to follow-up. By the time this 
study was undertaken, 36 patients died of their disease after a 
mean survival of 16.27 months (range 1–54 months).
Immunohistochemistry
We chose a representative block for each tumor for 
immunohistochemical analysis. A 4 μm thick section 
was cut from each formalin fixed and paraffin-embedded 
tumor tissue block. The sections were deparaffinized, 
rehydrated, immersed in 3% H2O2 for 30 min and heated 
in a microwave at 750 watts in citrate buffer (pH 6.0) for 
20 min. The tissue sections were then incubated with Ultra 
V block (Labvision, Freemont, CA, USA) for 5 min at 
room temperature before applying the primary antibody. 
Then, sections were automatically (autostainer-480-LV1, 
Labvision, USA) immunostained using a primary antibody 
against “fascin” (FCN01, 1:80, Mouse Monoclonal Ab, 
Neomarkers, Fremont, CA, USA) with the avidin-biotin 
peroxidase detection technique (UltraVision Large Volume 
Detection System, Anti-Polyvalent, horseradish peroxidase; 
LabVision, Fremont, CA, USA). The internal positive 
control was vascular endothelial cell fascin staining for the 
same slide. A negative control was obtained by applying the 
same protocol without the primary antibody. 
Evaluation of Fascin Expression by 
Immunohistochemistry
For each case, a minimum of five 400x magnification 
fields of all immunohistochemically stained slides were 
reviewed by two pathologists. Fascin immunoreactivity in 
each tumor was verified by the labeling of the endothelial 
cells of microvessels in each specimen. Cytoplasmic staining 
of fascin was recorded as a positive signal. The intensity of 
the immunohistochemical staining was categorized into three 
groups by comparing the staining intensity of tumor cells 
with the staining intensity of the vascular endothelial cells: 
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1+ (weak) = weaker than endothelial cells, 2+ (moderate) = 
same intensity as endothelial cells and 3+ (strong) = stronger 
than endothelial cells.13 The intensity score for each case was 
also characterized on the basis of the predominant area of 
intensity (invasive fronts of the tumor, other areas, or both). 
The percentage of positively stained cells was assessed semi-
quantitatively and grouped from 1 to 4 as follows: 1=0-10%, 
2=11-25%, 3=26-50% and 4=51-100%. We calculated the 
fascin “immunohistochemical score (IHS)” (0-12) for each 
case by multiplying the semi-quantitative staining intensity 
score (0-3) and the percentage of cells that were fascin 
positive (0-4). According to the IHS, we categorized cases 
into 3 groups as follows: 0 (negative), IHS≤10 and IHS>10.
Statistical analysis
SPSS software v.13.0 was used for the statistical analysis. 
p<0.05 was considered to be statistically significant. 
χ2 tests were used to measure the significance of the 
relationships between the nominalized immunoreactive fascin 
intensity, distribution percentages and clinicopathological 
characteristics. Survival analysis was carried out by the 
Kaplan-Meier method.
RESULTS
Fascin immunoreactivity was detected in 59 (35.3%) 
of all cases. Fascin immunoreactivity was observed in 
the cytoplasm of neoplastic cells in the tumor. No fascin 
immunoreactivity was present in the adjacent non-neoplastic 
epithelium. Immunoreactivity was also observed in 
endothelial cells of vessels in the tumor stroma and was used 
as an internal control. Fascin immunoreactivity was strong in 
10 (6.0%), moderate in 25 (14.9%) and weak in 24 (14.4%) 
cases. While strong immunoreactivity was generally (60.0%) 
widespread (>50%) in the tumors, weak immunoreactivity 
was often (66.7%) focal (<10%) (p:0.0001) (Table 1). Strong 
or moderate immunoreactivities were mostly observed 
(90.0% and 80.0%, respectively) in the invasive fronts of the 
tumors or in both the invasive fronts and other tumor areas. 
However, weak immunoreactivity was generally (58.3%) 
observed in other areas of the tumor (p:0.0001) (Table 1). 
Both the intensity and distribution of fascin 
immunoreactivity were associated with lymph node 
metastasis and tumor stage (Table 2 and 3). The intensity 
of fascin immunoreactivity was also associated with 
tumor location. Tumors with fascin IHS>10 were larger 
than (4.9±3.3 vs. 4.5±1.7) those without fascin expression 
(p=0.005). The association between fascin expression 
and age, gender, depth of invasion, distant metastasis 
or histological grade was not significant (NS). Fascin 
immunoreactivity was present in 5 of 10 mucinous 
carcinomas, with weak positivity in 4 cases and moderate 
positivity in the remaining case. Moreover, one signet ring 
cell carcinoma was negative for fascin expression. 
Table 1 - Comparison of fascin intensity with fascin distribution and location in colorectal carcinomas 
Fascin Intensity
pWeak (1+)
(n=24)
(%)
Moderate (2+)
(n=25)
(%)
Intense (3+)
(n=10)
(%)
Fascin distribution in the tumor
     0-9% 16 (66.7) 8 (32.0) 1 (10.0)
0.0001
     10-25% 4 (16.7) 10 (40.0) 1 (10.0)
     26-50% 3 (12.5) 5 (20.0) 2 (20.0)
     51-100% 1 (4.2) 2 (8.0) 6 (60.0)
Fascin location in the tumor
Invasive fronts or invasive fronts + other areas 10 (41.7) 20 (80.0) 9 (90.0)
0.0001
Only other areas 14 (58.3) 5 (20.0) 1 (10.0)
Figure 1 - Negative control (A), weak (B), moderate (C) and strong (D) 
staining.
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A fascin IHS >10 was statistically significantly more 
commonly observed in tumors with lymph node metastasis 
(p:0.005) and more often present in tumors located in the 
right colon (p:0.020) (Table 4). Similarly, higher stage (stage 
III/IV) tumors had significantly higher immunohistochemical 
scores (p:0.011). The percentage of cases with fascin IHS 
>10 was higher in the T3/T4 group (23.3%) compared 
to the T1/T2 group (5.9%). However, this difference was 
not statistically significant. Moreover, a mild to moderate 
correlation was observed between the number of positive 
lymph nodes and fascin immunoreactivity (r:0.373, 
p:0.001). There was a stronger correlation between fascin 
immunoreactivity in the invasive borders of tumors and 
lymph node metastasis (r:0.747, p:0.005). 
In stage III/IV tumors, while two-year survival was 
92.2% in tumors without fascin immunoreactivity, survival 
was 68.2% in tumors with fascin IHS≤10 and only 60.0% in 
tumors with fascin IHS>10 (log rank:11.836, p:0.003). 
DISCUSSION
Fascin is expressed in many types of transformed 
epithelial cell lines and in several solid neoplasms. Fascin 
expression has been correlated with tumor stage12, 13,21,22 and 
grade,9,12,22 pT class,12,13 lymph node involvement12,13,21,23 
and recurrence.12 Furthermore, fascin expression is related 
to poor prognosis for some solid neoplasms because it 
facilitates invasion and metastasis.4,9,11-13,15,24,25 
In the present study, no immunohistochemical staining 
was observed in the normal colonic epithelium adjacent to 
the tumor, in accordance with previous reports.1,15 Jawhari 
et al. demonstrated that fascin was not detectable in normal 
colonic epithelium, but was dramatically up-regulated in 
colorectal adenocarcinoma.1 Moreover, scattered fascin 
expression was demonstraed in control specimens of 
normal colonic glandular epithelia in the study by Tsai et 
al.17 Additionally, fascin was up-regulated in a proportion 
of adenomas, where its expression was often focal.15 
Furthermore, only 16% of adenomas showed fascin 
expression in greater than 10% of the tumor cells. Finally, 
Tsai et al. found that higher fascin immunostaining scores 
were significantly associated with advanced dysplasia in 
colorectal adenomas.17
In this study, we observed fascin immunoreactivity 
in 35.3% of all cases and noted that fascin positivity was 
significantly higher in right colon adenocarcinomas. In a study 
Table 2 - Relationship between fascin intensity and clinicopathological characteristics in 167 colorectal carcinomas
Parameters
Fascin Intensity
pAbsent(n=108)
(%)
Weak (1+)
(n=24)
(%)
Moderate (2+)
(n=25)
(%)
Intense (3+)
(n=10)
(%)
Age 
     ≤60
     >60
50 (69.4)
58 (61.1)
7 (9.7)
17 (17.9)
9 (12.5)
16 (16.8)
6 (8.3)
4 (4.2) 0.258
Gender
     M
     F
64 (72.1)
44 (60.4)
16 (13.1)
8 (15.1)
19 (9.8)
6 (17.9)
7 (4.9)
3 (6.6) 0.422
Location
    Rectum
    Left colon
    Right colon
39 (69.6)
50 (71.4)
19 (46.3)
9 (16.1)
4 (5.7)
11 (26.8)
7 (12.5)
11 (15.7)
7 (17.1)
1 (1.8)
5 (7.1)
4 (9.8)
0.028
T
    T1/T2
    T3/T4
12 (70.6)
96 (64.0)
5 (29.4)
19 (12.7)
0
25 (16.7)
0
10 (6.7)
0.070
N
    N0
    N1
    N2
68 (73.9)
23 (57.5)
17 (48.6)
16 (17.4)
2 (5.6)
6 (17.1)
4 (4.3)
14 (35.0)
7 (20.0)
4 (4.3)
1 (2.5)
5 (14.3) < 0.0001
M
    M0
    M1
91 (66.4)
17 (56.7)
20 (14.6)
4 (13.3)
17 (12.4)
8 (26.7)
9 (6.6)
1 (3.3) 0.244
Stage
    I/II
    III/IV
64 (72.7)
44 (55.7)
14 (19.9)
10 (12.7)
6 (6.8)
19 (24.1)
4 (4.5)
6 (7.6) 0.011
Tumor grade
    G1
    G2
    G3
2 (33.3)
87 (67.4)
12 (63.2)
3 (50.0)
14 (10.9)
2 (10.5)
1 (16.7)
20 (15.5)
3 (15.8)
0
8 (6.2)
2 (10.5)
0.168
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by Hashimoto et al. using conventional tissue sections from 
35 adenocarcinomas, 26% showed fascin expression in greater 
than 10% of tumor cells.15 When examining fascin expression 
in 228 advanced colonic adenocarcinoma patients, Puppa et 
al. found that fascin was detected in 71% of tumors.16 In both 
these studies, fascin immunoreactivity was more prevalent in 
tumors located in the proximal colon.15, 16 
Interestingly, no association was identified between 
fascin expression and age or gender. This observation was 
in accordance with the clinically annotated tumors, where 
fascin immunoreactivity was not associated with age and 
gender.15 However, in a recent study, fascin correlated 
significantly with the female sex.16 
Although immunohistochemical scores were higher 
for poorly differentiated tumors in the present study, this 
finding was not statistically significant. In a study by Tsai 
et al., fascin immunohistochemistry was performed in tissue 
microarrays of 91 surgical specimens. Tsai et al. found that 
higher fascin immunostaining scores were significantly 
associated with high-grade histopathological differentiation 
of colorectal adenocarcinomas.17 Similarly, another study 
found a significant correlation between fascin expression and 
tumor grade and mucinous differentiation.16 In the present 
study, no differences were observed in fascin expression 
between mucinous and nonmucinous adenocarcinomas. In 
mucinous adenocarcinomas, fascin immunoreactivity was 
generally weak in half of the cases. However, more studies 
with a large number of cases are needed to analyze the role 
of fascin in mucinous colorectal adenocarcinomas.
We also noted an association between fascin expression 
and the N stage of colorectal carcinomas. Specifically, 
strong immunoreactivity in the invasive front of tumors 
was correlated with the number of metastatic lymph 
nodes. The association of fascin expression with lymph 
node involvement has also been documented for other 
gastrointestinal cancers such as oesophageal13 and gastric 
carcinomas,12 as well as pulmonary neoplasms.21, 26 Tsai 
et al. reported that higher fascin immunostaining scores 
were significantly associated with an advanced T stage of 
colorectal carcinomas.17 In their study, higher fascin scores 
were also related with more advanced M and N stages of 
colorectal carcinomas. However, in the study by Hashimoto 
et al. with clinically annotated colorectal carcinomas, fascin 
immunoreactivity was not associated with TNM stage.15 In a 
recent study, fascin expression was found to be significantly 
correlated with the number of metastatic lymph nodes, 
extranodal tumor extensions and the occurrence of distant 
metastases.16 
Table 3 - Relationship between fascin distribution and clinicopathological characteristics in 167 colorectal carcinomas
Fascin Distribution
Parameters 0(n=108)
0-9%
(n=25)
10-25%
(n=15)
26-50%
(n=10)
50-100%
(n=9) p
Age
    <60
    >60
50 (69.4)
58 (61.1)
7 (9.7)
18 (18.9)
7 (9.7)
8 (8.4)
3 (4.2)
7 (7.4)
5 (6.9)
4 (4.2)
0.390
Gender
    M
    F
64 (60.4)
44 (72.1)
17 (16.0)
8 (13.1)
12 (11.3)
3 (4.9)
8 (7.5)
2 (3.3)
5 (4.7)
4 (6.6)
0.375
Location
    Rectum
    Left colon
    Right colon
39 (69.6)
50 (71.4)
19 (46.3)
10 (17.9)
8 (11.4)
7 (17.1)
4 (7.1)
5 (7.1)
6 (14.6)
2 (3.6)
3 (4.3)
5 (12.2)
1 (1.8)
4 (5.7)
4 (9.8)
0.146
T
    T1/T2
    T3/T4
12 (70.6)
96 (64.0)
4 (23.5)
21 (14.0)
1 (5.9)
14 (9.3)
0
10 (6.7)
0
9 (6.0)
0.496
N
    0
    1
    2
68 (73.9)
23 (57.5)
17 (48.6)
15 (16.3)
5 (12.5)
5 (14.3)
3 (3.3)
7 (17.5)
5 (14.3)
3 (3.3)
4 (10.0)
3 (8.6)
3 (3.3)
1 (2.5)
5 (14.3)
0.010
M
    0
    1
91 (66.4)
17 (56.7)
19 (13.9)
6 (20.2)
12 (8.8)
3 (10.0)
7 (5.1)
3 (10.0)
8 (5.8)
1 (3.3)
0.682
Stage
    I/II
    III/IV
64 (72.7)
44 (55.7)
14 (15.9)
11 (13.9)
3 (3.4)
12 (15.2)
4 (4.5)
6 (7.6)
3 (3.4)
6 (7.6)
0.034
Tumor grade
    G1
    G2
    G3
2 (33.3)
87 (67.4)
12 (63.2)
3 (50.0)
18 (14.0)
1 (5.3)
1 (16.7)
12 (9.39
1 (5.3)
0
5 (3.9)
3 (15.8)
0
7 (5.4)
2 (10.5)
0.246
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In the present study, although the mean follow-up 
was not long; overall survival in stage III/IV tumors was 
shorter for cases with fascin expression compared to those 
without. In the study of Hashimoto et al., fascin expression 
was investigated using a tissue microarray containing 
cores of 158 colorectal adenocarcinomas with a mean of 
38 months of clinical follow-up.15 Patients with stage III/
IV adenocarcinomas with strong fascin immunoreactivity 
had a worse prognosis than patients with low or no fascin 
immunoreactivity (3-year overall survival of 11% vs. 43% 
for fascin-negative patients; p = 0.023). Similarly, a study of 
fascin expression in 228 advanced colonic adenocarcinoma 
patients with a long follow-up period revealed that patients 
with fascin-expressing tumors had a shorter disease-free and 
overall survival compared to patients with fascin-negative 
tumors. Moreover, fascin immunoreactivity emerged as an 
independent prognostic factor in the multivariate analysis.16 
Moreover, patients with the same tumor stages could 
be stratified in different risk categories for relapse and 
progression according to fascin expression.
The contribution of fascin to the migration of cancer cells 
and its relationship with beta-catenin were recently analyzed.14,27 
Vignjevic et al. identified fascin as a target of beta-catenin-
TCF signaling in colorectal cancer cells. Fascin mRNA and 
protein expression were increased in primary cancers in a 
stage-dependent manner. Fascin was exclusively localized at 
the invasive front of tumors that also displayed the nuclear 
localization of beta-catenin, which is a hallmark of activated 
Wnt signaling. Their studies show that fascin expression is 
tightly regulated during the development of colon cancer 
metastases and that it is a novel target of beta-catenin-TCF 
signaling. They proposed that transient up-regulation of fascin 
in colorectal cancer promotes the acquisition of migratory and 
invasive phenotypes that lead to metastasis. Moreover, they 
also found that the expression of fascin is down-regulated when 
tumor cells reach their metastatic destination, where migration 
ceases and proliferation is enhanced.14 To understand the 
functional and mechanistic contributions of fascin, Hashimoto 
et al. used inducible short hairpin RNA (shRNA) to knockdown 
fascin expression in human colon carcinoma cells derived 
from an aggressive primary tumor. Fascin depletion led to 
decreased numbers of filopodia and an altered morphology 
of cell protrusions, decreased Rac-dependent migration on 
laminin, decreased turnover of focal adhesions, and decreased 
xenograft tumor development and metastasis in vivo. They 
further showed that both the actin bundling and active PKC-
binding activities of fascin were required for the organization of 
filopodial protrusions and tumor metastasis. Thus, these authors 
concluded that fascin contributes to carcinoma migration and 
metastasis through parallel pathways that have an impact 
on multiple subcellular structures that are needed for cell 
migration.27 
Over the past 10 years, our knowledge of the genes 
and genetic pathways associated with cancer development 
and progression has been greatly expanded. From the 
perspective of colorectal carcinomas, one of the important 
carcinogenetic factors is epidermal growth factor receptor 
(EGFR), which contributes to the development and 
progression of several carcinomas and is overexpressed 
in 50-80% of colorectal cancers.28 Gain-of-function 
KRAS mutations lead to EGFR-independent activation of 
intracellular signaling pathways, resulting in tumor cell 
proliferation, protection against apoptosis, increased invasion 
and metastasis.29 For EGFR-targeted therapy, standardized 
testing for KRAS mutation status has been recommended.30 
Another example is CD133, the expression of which 
correlates with liver metastasis and has a prognostic impact 
in colorectal carcinomas.31 The combination of CD133 and 
nuclear beta-catenin expression was shown to be a powerful 
tool to identify high-risk cases of stage IIA colon cancer.32
CONCLUSION
Fascin expression is present in approximately one third 
Table 4 - Immunohistochemical scores of fascin expression 
in colorectal carcinomas
Parameters
Immunohistochemical score of 
fascin expression
p
0
n=108(%)
1-10
n=23(%)
>10
n=36(%)
Age
       <60
       >60
50 (69.4)
58 (61.1)
6 (8.3)
17 (17.9)
16 (22.2)
20 (21.1)
0.203
Gender
       M
       F
44 (72.1)
64 (60.4)
7 (11.5)
16 (15.1)
10 (16.4)
26 (24.5)
0.304
T
       T1/T2
       T3/T4
12 (70.6)
96 (64.0)
4 (23.5)
19 (12.7)
1 (5.9)
35 (23.3)
0.168
N
       0
       1
       2
68 (73.9)
23 (57.5)
17 (48.6)
14 (14.3)
5 (12.5)
4 (11.4)
10 (10.9)
12 (30.0)
14 (40.0)
0.005
M
       0
       1
91 (66.4)
17 (56.7)
18 (13.1)
5 (16.7)
28 (20.4)
8 (26.7)
0.598
Location
    Rectum
    Left colon
    Right colon
39 (69.6)
50 (71.4)
19 (46.3)
10 (17.9)
6 (8.6)
7 (17.1)
7 (12.5)
14 (20.0)
15 (36.6)
0.020
Stage
    I/II
    III/IV
64 (72.7)
44 (55.7)
13 (14.8)
10 (12.7)
11 (12.5)
25 (31.6)
0.011
Tumor grade
    G1
    G2
    G3
2 (33.3)
87 (67.4)
12 (63.2)
3 (50.0)
16 (12.4)
1 (5.3)
1 (16.7)
26 (20.2)
6 (31.6)
0.228
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